GlassScriptPhysician profile
Stephen M Ginn
NPI 1861466658
$902.32
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.14 · 2020: $11.64 · 2021: $83.01 · 2022: $202 · 2023: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $532.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $188.31 | 2020-2023 | Repatha |
| Philips North America LLC | $175.70 | 2022-2023 | |
| Edwards Lifesciences Corporation | $129.05 | 2023 | Pascal |
| Boston Scientific Corporation | $102.66 | 2023 | Watchman Access System |
| Pfizer INC. | $81.00 | 2021-2023 | |
| Astellas Pharma US INC | $59.99 | 2019 | |
| Abbott Laboratories | $42.56 | 2022-2023 | Amplatzer Talisman |
| Scpharmaceuticals INC. | $33.07 | 2023 | |
| Abiomed | $23.84 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.11 | 2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $18.02 | 2021 | |
| Merck Sharp & Dohme LLC | $14.86 | 2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $13.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Ginn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.